Relief for Ramdev

THE Supreme Court’s decision to close contempt proceedings against Ramdev and Acharya Balkrishna in the Patanjali misleading ads case may seem like a reprieve, but it comes with a stern warning that cannot be ignored. While the court accepted their apology, it did so begrudgingly, reflecting its deep frustration with Patanjali’s brazen disregard for legal and ethical standards. Patanjali’s misleading claims about Coronil being a cure for Covid-19 were not just irresponsible; they were dangerous. At a time when the nation was grappling with a deadly pandemic, such unfounded claims had the potential to mislead millions. The Indian Medical Association rightfully took a stand, labelling Patanjali’s actions as a ‘blatant lie’ and pushing for accountability. The company repeatedly tried to deceive the public with dubious advertisements, even after being warned by the court.

The Uttarakhand State Licensing Authority, which eventually suspended the manufacturing licences of 14 Patanjali products, was also not spared by the court. The authority’s inaction for months, until it was forced to act, earned it a sharp rebuke from the Bench, which accused it of being complicit in Patanjali’s continued violations. This delay in enforcement not only undermines regulatory integrity but also raises questions about the authority’s commitment to public health. Patanjali’s attempts to downplay the severity of its misconduct through half-hearted apologies have rightfully angered the court. Its ‘absolute defiance’ and lack of genuine remorse were met with the court’s order for a full-page public apology.

While Ramdev and Balkrishna may have escaped immediate legal consequences, the apex court’s warning is clear: any further transgressions will be met with the full force of the law. Patanjali’s actions have not only eroded public trust but also exposed the company to the risk of far harsher penalties if it continues down this reckless path.